Literature DB >> 7495692

Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors.

C M Jewell1, J C Webster, K L Burnstein, M Sar, J E Bodwell, J A Cidlowski.   

Abstract

We have analyzed structural and functional features of the human glucocorticoid receptor (hGR) for their effects on receptor subcellular distribution. COS 1 cells transiently transfected with wild type and mutant hGR cDNAs were assessed immunocytochemically using well-characterized antipeptide antibodies to the hGR. The effect of administration of steroid hormones (and the antiglucocorticoid RU486) on receptor localization was evaluated. Unliganded wild type receptors expressed in COS 1 cells were predominately cytoplasmic. Addition of glucocorticoids or the glucocorticoid receptor antagonist, RU486, resulted in complete translocation of these receptors into the nucleus whereas non-glucocorticoid steroids or dibutyryl cAMP were not effective in promoting nuclear translocation. Thus, nuclear translocation was specific for steroids capable of high affinity binding to the hGR. To elucidate the potential role of receptor domains in receptor localization, COS 1 cells transiently transfected with various receptor cDNA mutants were analyzed in a similar manner. Translocation of an hGR deletion mutant lacking the majority of the amino terminus (deletion of amino acids 77-262) was identical to the wild type receptor despite the absence of a transactivation domain. Receptors in which the DNA binding domain was either partially or totally deleted showed an impaired capacity to undergo hormone-inducible nuclear translocation. Deletion of the hinge region of the hGR (which also contains part of the nuclear localization signal, NL1) resulted in receptor localization in the cytoplasm. Mutants in the ligand binding domain exhibited two localization phenotypes, exclusively nuclear or cytoplasmic. Receptor mutants truncated after amino acid 550 were found in the nucleus in the presence and absence of hormone consistent with the existence of nuclear localization inhibitory sequences in the ligand binding domain of the receptor. However, a linker insertion mutant (at amino acid 582) which results in a receptor deficient in ligand binding did not undergo nuclear translocation indicating that nuclear localization inhibitory sequences were intact in this mutant. The role of receptor phosphorylation on hormone induced nuclear translocation was also examined. Mouse glucocorticoid receptors which contained mutations of certain hormone inducible phosphorylation sites exhibited translocation properties similar to wild type mGR indicating that these phosphorylation sites on the receptor do not play a major role in hormone inducible nuclear translocation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495692     DOI: 10.1016/0960-0760(95)00174-x

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  12 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

2.  Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor.

Authors:  J G Savory; B Hsu; I R Laquian; W Giffin; T Reich; R J Haché; Y A Lefebvre
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury.

Authors:  J Xu; G M Kim; S H Ahmed; J Xu; P Yan; X M Xu; C Y Hsu
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

4.  Protein phosphatase 1 alpha enhances glucocorticoid receptor activity by a mechanism involving phosphorylation of serine-211.

Authors:  Melanie Patt; Joël Gysi; Nourdine Faresse; John A Cidlowski; Alex Odermatt
Journal:  Mol Cell Endocrinol       Date:  2020-06-22       Impact factor: 4.102

5.  Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance.

Authors:  J C Webster; R H Oakley; C M Jewell; J A Cidlowski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

Review 6.  Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch.

Authors:  Renato Malcher-Lopes; Alier Franco; Jeffrey G Tasker
Journal:  Eur J Pharmacol       Date:  2008-01-31       Impact factor: 4.432

7.  Differential effect of glucocorticoid receptor antagonists on glucocorticoid receptor nuclear translocation and DNA binding.

Authors:  Francesca Spiga; David M Knight; Susanne K Droste; Becky Conway-Campbell; Yvonne Kershaw; Cliona P MacSweeney; Fiona J Thomson; Mark Craighead; Bernard W M M Peeters; Stafford L Lightman
Journal:  J Psychopharmacol       Date:  2010-01-21       Impact factor: 4.153

Review 8.  Import and export of nuclear proteins: focus on the nucleocytoplasmic movements of two different species of mammalian estrogen receptor.

Authors:  Thomas Sebastian; S Sreeja; Raghava Varman Thampan
Journal:  Mol Cell Biochem       Date:  2004-05       Impact factor: 3.396

9.  Cardiac corticosteroid receptors mediate the enlargement of the ovine fetal heart induced by chronic increases in maternal cortisol.

Authors:  Seth A Reini; Garima Dutta; Charles E Wood; Maureen Keller-Wood
Journal:  J Endocrinol       Date:  2008-05-21       Impact factor: 4.286

10.  Dynamic regulation of mitochondrial function by glucocorticoids.

Authors:  Jing Du; Yun Wang; Richard Hunter; Yanling Wei; Rayah Blumenthal; Cynthia Falke; Rushaniya Khairova; Rulun Zhou; Peixiong Yuan; Rodrigo Machado-Vieira; Bruce S McEwen; Husseini K Manji
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.